
William Smith
Senior Fellow and Director of Life Sciences Initiative at Pioneer Institute; healthcare policy expert focused on biopharmaceutical regulation and the 340B drug pricing program.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Jun 25, 2026
Bill Smith: How 340B Became A Hospital Profit Center
3:14
3:18
3:24
3:38
5:16

Duane SchulthessHOST
Why were you approached to do this study? What was the methodology and what were you asked to do?

William SmithGUEST
Well, the study was instigated by Cancer Care, which is a patient advocacy organization for cancer patients.

William SmithGUEST
And they had been getting anecdotal reports from their patients that they went into 340B hospitals and they couldn't get charity care or that the hospital wouldn't accept Medicaid.

William SmithGUEST
The whole point of this statute was to give more resources to these safety net hospitals and clinics so that they could treat more low-income patients.

Duane SchulthessHOST
Does this imply then that the charity hospitals that are being covered and getting tax breaks are actually providing less uninsured care, which is sort of the whole point of the program?